Trusted News Discovery Since 2008
{{/content}}
United States: FDA Approves Sandoz Denosumab Biosimilars - Goodwin Procter LLP
Credit: Mondaq- Published on March 18, 2024
On March 5, Sandoz announced that the FDA approved its denosumab biosimilars, WYOST and JUBBONTI, as interchangeable with Amgen's XGEVA and PROLIA.
You are here
Related news from verified sources
On February 16, 2024, the FDA approved Iovance's AMTAGVI, the first approved cellular therapy for the treatment of adult patients with unresectable or metastatic...
on March 5, 2024 • Mondaq